Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The parent trials primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints
Saxenda is specifically approved for weight management in individuals with obesity or those with a BMI of 27+ who have obesity-related conditions (e.g., high blood pressure, type 2 diabetes)
Nevertheless, our findings also suggest an increased efficacy of GLP-1RAs in a post-bariatric population, compared with people with obesity with no history of bariatric interventions
A heart rate increase of 5 to 10 BPM without symptoms is expected and generally acceptable
US$ 28.60
US$ 21.89
US$ 24.79
US$ 25.24
US$ 29.20
US$ 27.97
US$ 23.11
US$ 21.63
